Metastases Clinical Trial
Official title:
Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer
This study seeks to identify risk factors associated with the development of a jaw condition seen in patients with cancer treated with certain medications.
The goal of this research is to build an index of risk for estimating an individual's risk
of developing osteonecrosis of the jaw (ONJ). The bisphosphonates are an important
supportive therapy in the care of patients with metastatic bone disease; they are able to
prevent catastrophic events such as fracture and spinal cord compression. However, ONJ has
been associated with the use of the bisphosphonates and ONJ carries significant morbidity.
Presently, there are insufficient data to calculate the ONJ risk benefit ratio of
bisphosphonate use. An ONJ risk assessment tool would improve both the oncologist's and the
dental health professional the ability to anticipate and potentially mitigate oral
toxicities from bisphosphonate therapy.
This protocol consists of a case (ONJ) control (no ONJ) study to identify factors associated
with the risk of ONJ and to build an index predictive of an individual's risk of developing
ONJ. The index of ONJ risk will be comprised of clinical, epidemiologic and genetic factors
;
Observational Model: Case Control, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02156700 -
Quantitative Real-time Ultrasound Elastography for Characterisation of Liver Tumors
|
N/A | |
| Terminated |
NCT01403324 -
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
|
N/A | |
| Completed |
NCT00094653 -
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
|
Phase 3 | |
| Completed |
NCT00091832 -
Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT00080301 -
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
|
Phase 3 | |
| Completed |
NCT00446446 -
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
|
Phase 2 | |
| Completed |
NCT01678664 -
Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
|
Phase 2 | |
| Completed |
NCT00083720 -
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
|
Phase 2 | |
| Completed |
NCT00093080 -
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
|
Phase 2 | |
| Completed |
NCT00096967 -
A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
|
Phase 3 | |
| Completed |
NCT00097487 -
A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane
|
N/A | |
| Completed |
NCT00752570 -
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05195710 -
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
|
Phase 1 | |
| Completed |
NCT00106418 -
A Research Study for Patients With Prostate Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04825470 -
Liver Transplantation for Unresectable GIST Liver Metastases
|
N/A | |
| Active, not recruiting |
NCT02414269 -
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
|
Phase 1/Phase 2 | |
| Terminated |
NCT01759238 -
Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT00107861 -
Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases
|
Phase 1/Phase 2 | |
| Completed |
NCT00095108 -
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
|
Phase 1 | |
| Terminated |
NCT00099281 -
DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer
|
Phase 3 |